Aflibercept sales continue to soar

Regeneron yesterday reported that 2016 aflibercept sales were up 24% to $3.323 billion from $2.676 billion in 2015.

Fourth quarter US net sales increased 15% to $858 million, while global sales totaled $496 million and $1.872 billion for the quarter and full year, respectively.

Revenues totaled $4.860 billion in 2016, an 18% increase compared with $4.104 billion in 2015.

"The hard work of our scientists over the last decades has brought Regeneron to the next phase of our evolution - this year we anticipate launching two additional important therapies, significantly expanding our impact for patients with serious diseases and our company's growth potential," said Leonard S. Schleifer, MD, PhD, president and CEO at Regeneron. 

Regeneron’s pipeline includes sarilumab, an antibody targeting IL-6R. In November, a phase 3 trial showed sarilumab outperformed adalimumab as a monotherapy for rheumatoid arthritis.